SML2216

Takinib

≥98% (HPLC), TAK1/MAP3K7 kinase inhibitor, powder

• Synonim(y): N1-(1-Propyl-1H-benzimidazol-2-yl)-1,3-benzenedicarboxamide
• Wzór empiryczny (zapis Hilla): C₁₈H₁₈N₄O₂
• Numer CAS: 1111556-37-6
• Masa cząsteczkowa: 322.36
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Nazwa produktu: Takinib, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: CCCN1C2=CC=CC=C2N/C1=N\C(C3=CC(C(N)=O)=CC=C3)=O

Opis

General description

Takinib belongs to the aminobenzimidazole class of inhibitors.

Application

Takinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurkat cells.

Biochem/physiol Actions

TAK-1 inhibitor

Takinib is a selective inhibitor of TAK1/MAP3K7 kinase, which is a member of the MAP3K family and a key regulator of cell death. It binds in the TAk1 ATPbinding pocket with an IC50 value of 9.5 nM. Takinib selectively induced apoptosis following TNF-α stimulation in rheumatoid arthritis and breast cancer.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable